Nanobiotix S.A. (NBTX) vs uniQure N.V. (QURE)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Nanobiotix S.A. (NBTX) has outperformed uniQure N.V. (QURE) over the past year, gaining 26.6% versus a loss of 30.4%. Over five years, NBTX leads with a +214.0% price change compared with -32.9% for QURE. uniQure N.V. is the larger company by market cap ($1.36 billion vs $1.35 billion), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | NBTX | QURE |
|---|---|---|
| Share price | $26.50 | $19.35 |
| Market cap | $1.35B | $1.36B |
| 1-day change | -2.98% | -4.35% |
| YTD return | +14.62% | -19.14% |
| 1-year return | +26.61% | -30.42% |
| 5-year return | +213.98% | -32.86% |
| EPS (TTM) | $-1.27 | $-3.51 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $16.10M |
| Revenue growth (YoY) | — | -40.64% |
| Net income (latest FY) | — | $-198.97M |
| Gross margin | — | 89.53% |
| Operating margin | — | -1151.38% |
| Net margin | — | -1236.00% |
| 52-week high | $57.14 | $51.72 |
| 52-week low | $19.14 | $8.73 |
| Distance from 52-week high | -53.62% | -62.59% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +101.06% | +207.03% |
| Average volume | 148.94K | 2.26M |
| Shares outstanding | 50.95M | 70.14M |
| Employees | 98 | 221 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- NBTX has outperformed QURE by 57.0 percentage points over the past year.
About Nanobiotix S.A.
NBTX stock →Nanobiotix S.A. operates as a clinical-stage biotechnology that focuses on developing product candidates for the treatment of cancer and other unmet medical needs.
Health Care · Biotechnology: Pharmaceutical Preparations · 98 employees
About uniQure N.V.
QURE stock →uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases in the United States.
Health Care · Biotechnology: Pharmaceutical Preparations · 221 employees
NBTX vs QURE FAQ
Which is bigger, Nanobiotix S.A. or uniQure N.V.?
uniQure N.V. (QURE) is larger, with a market capitalization of $1.36B compared with $1.35B for Nanobiotix S.A. (NBTX).
Which stock has performed better over the past year, NBTX or QURE?
NBTX returned +26.61% over the past 12 months, compared with -30.42% for QURE (price return, excluding dividends). Past performance does not predict future results.
Are Nanobiotix S.A. and uniQure N.V. in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.